Alector, Inc. Board of Directors

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Dr. Arnon Rosenthal Ph.D.

Dr. Arnon Rosenthal Ph.D.

Co-Founder, CEO & Director

Ms. Clare Hunt M.B.A.

Ms. Clare Hunt M.B.A.

Chief People Officer

Dr. Marc Grasso M.D.

Dr. Marc Grasso M.D.

CFO, Principal Financial Officer & Principal Accounting Officer

Ms. Norah Conway

Ms. Norah Conway

Senior Vice President of Portfolio & Program Management

Ms. Virginia DeJesus-Rueff M.B.A.

Ms. Virginia DeJesus-Rueff M.B.A.

Chief of Staff & Head of Strategy

Ms. Katie Hogan

Ms. Katie Hogan

Senior Director of Corporate Communication & Investor Relations

Ms. Kristina Cutter M.P.H.

Ms. Kristina Cutter M.P.H.

Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer

Dr. Saraswati Kenkare-Mitra Ph.D.

Dr. Saraswati Kenkare-Mitra Ph.D.

President and Head of Research & Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.